The CAP24 system allows clinicians to measure individual neural responses and adjust stimulation automatically with every pulse. This design addresses a critical gap in the market, as the surgical segment accounts for roughly 30% of all spinal cord stimulation implants in the United States. During the initial rollout, neurosurgeons and orthopedic spine specialists reported that the lead’s low-profile, anatomically contoured shape facilitates stable placement and consistent therapy delivery.

Erika Petersen, a professor of neurosurgery at the University of Arkansas for Medical Sciences, noted that the device’s ability to provide real-time physiologic feedback enables a more predictable treatment experience for patients. The technology builds on the clinical outcomes of the EVOKE study, which reported that over 90% of patients who responded to the therapy at three months maintained those results at the 36-month mark. For Saluda Medical, this release marks a broader push to bring closed-loop therapy to patients requiring surgical paddle leads, rather than the percutaneous options previously available.